Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Bonus Content
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Article Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon’s “Hidden” Company
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Abbott Laboratories’ stock price recently hit a 52-week low, closing just above $100 in the final trading days of March. This sharp drop has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation suggests a potential disconnect between market sentiment and operational reality. The key question for long-term investors is whether the market’s pessimism is justified or whether a meaningful value opportunity has emerged. Separating the Signal From the NoiseAbbott’s decline stems from two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in that division, driven mainly by market-share losses in the U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the issue and laid out a turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026 aimed at restoring volume and returning the segment to growth in the second half of the year. The second factor is external and broader: a rotation of capital across the market. In periods of economic optimism, investors often move money out of stable, defensive sectors like the healthcare sector and into higher-beta areas — for example, artificial intelligence (AI) and the energy sector — in pursuit of faster returns. That broad trend has pressured many fundamentally sound healthcare stocks, including Abbott, for reasons largely unrelated to their individual operations or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition navigates a short-term recovery, Abbott’s core remains healthy, driven by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a powerful counterbalance to the isolated weakness in Nutrition, and the company’s underlying strength is most evident in these high-performing areas.
Medical Devices: The Medical Devices business is gaining momentum, fueled by market-leading innovation across critical-care categories. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors continues to be a standout growth driver. This product line, which allows users to monitor glucose without routine fingersticks, generated more than $7.5 billion in sales in 2025 and remains central to Abbott’s sustained growth. Cardiovascular Leadership: Abbott is also strong in cardiovascular care. Its Electrophysiology business delivered double-digit growth, while Structural Heart posted 8.7% organic growth. These gains reflect a portfolio of best-in-class products — including MitraClip and TriClip for minimally invasive valve repair — and a pipeline of innovations such as the recently FDA-approved Volt PFA System for atrial fibrillation. Abbott is not relying solely on its current portfolio. The company is making a major strategic move to secure future growth through the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for its non-invasive colon cancer test, Cologuard. This transaction would immediately position Abbott as a leader in the rapidly expanding market for cancer diagnostics, adding a high-growth vertical likely to contribute meaningfully to revenue over time. Professional analysts share this bullish view. Wall Street maintains a Moderate Buy consensus rating on the stock, and the average 12-month price target is $135.47 — implying potential upside of more than 30% from current levels and suggesting many analysts believe the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is a key attraction. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record reflects a strong commitment to returning capital to shareholders through multiple market cycles. The recent decline in Abbott’s stock price increases the yield for new investors: at current prices, Abbott yields about 2.5%, offering a higher income rate from a historically reliable payer. The dividend payout ratio is roughly 68% of earnings, but it represents only about 37% of cash flow — indicating Abbott generates more than enough cash to cover its dividend with room to support future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from its business fundamentals. Temporary headwinds in the Nutrition division and broader sector rotations have depressed the stock price, yet Abbott’s core growth engines are accelerating. Its dominant Medical Devices business continues to deliver strong results, the dividend remains a bedrock of reliability, and strategic moves like the Exact Sciences acquisition add attractive long-term catalysts. For investors with a multi-year perspective, the present valuation reveals a noteworthy gap between market price and intrinsic value that merits serious consideration. |
